A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Icotrokinra (Primary) ; Deucravacitinib
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms ICONIC-ADVANCE 1
- Sponsors Janssen Research & Development
- 08 Mar 2025 Primary endpoint (JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16) has been met.
- 08 Mar 2025 Primary endpoint (JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to () 2-Grade Improvement From Baseline to Week 16) has been met.
- 08 Mar 2025 Results published in the Johnson & Johnson Media Release.